Turnstone Logo.jpg
Turnstone Biologics Appoints William Waddill to its Board of Directors
April 16, 2024 09:00 ET | Turnstone Biologics Corp.
Turnstone Biologics appoints biotechnology industry veteran, William Waddill, to its Board of Directors.
Turnstone Logo.jpg
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights
March 21, 2024 17:06 ET | Turnstone Biologics Corp.
Turnstone reports fourth quarter and full year 2023 financial results and provides recent business highlights.
Turnstone Logo.jpg
Turnstone Biologics to Participate in Upcoming Investor Conferences
February 21, 2024 06:00 ET | Turnstone Biologics Corp.
Turnstone to present and participate in TD Cowen 44th Annual Global Health Care Conference and Leerink Partners Global Biopharma Conference 2024.
Turnstone Logo.jpg
Turnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare Conference
November 27, 2023 06:00 ET | Turnstone Biologics Corp.
Dr. Sammy Farah, President and CEO of Turnstone, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York.
Turnstone Logo.jpg
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 03, 2023 06:00 ET | Turnstone Biologics Corp.
Posters showcase Turnstone’s novel Selected TIL programs which are designed to selectively expand the most potent tumor-reactive T cells for solid tumors.
Turnstone Logo.jpg
Turnstone Biologics Expands Scientific Advisory Board with Appointment of Dr. Jeffrey S. Weber
October 30, 2023 06:00 ET | Turnstone Biologics Corp.
Internationally recognized cancer immunotherapy thought leader, Dr. Weber, will help guide Turnstone’s continued advancement of its Selected TIL therapies
Turnstone Logo.jpg
Turnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
September 28, 2023 06:00 ET | Turnstone Biologics Corp.
Turnstone Biologics to present preclinical data for its Selected TILs at SITC's 38th Annual Meeting.
Turnstone Logo.jpg
Turnstone Biologics Corp. Reports Second Quarter 2023 Financial Results and Provides Business Update
September 01, 2023 17:57 ET | Turnstone Biologics Corp.
Successfully closed upsized IPO, raising $88 million in gross proceeds to continue advancing pipeline of Selected TIL Therapy programsCash position expected to fund operations into second quarter of...
Turnstone Logo.jpg
Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering
July 21, 2023 02:15 ET | Turnstone Biologics Corp.
SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing new medicines to treat and cure...
Nurix.png
Nurix Therapeutics Presents New Preclinical Data Supporting NX-2127 and DeTIL-0255 Clinical Programs at the American Association for Cancer Research Annual Meeting
April 08, 2022 13:02 ET | Nurix Therapeutics, Inc.
Studies provide insight into bifunctional molecular mechanism and first in vivo demonstration of immunomodulatory imide drug (IMiD) activity of NX-2127, resulting in robust tumor cell killing Animal...